Côd QR

Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer

Immunotherapy is becoming essential in the management of advanced non-small cell lung cancer (NSCLC); however, the best treatment sequence remains to be determined. Some data suggest that immunotherapy prior to chemotherapy with paclitaxel/bevacizumab (PB) appears to be an interesting option. Here,...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Agathe Peyret, Clémentine Le Berrurier, Luc Heraudet, Tara Delon, Maéva Zysman, Mathieu Larroquette, Laura Leroy, Sophie Cousin, Charlotte Domblides
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2025-10-01
Cyfres:Frontiers in Oncology
Pynciau:
NSCLC
immunotherapy
chemotherapy
therapeutic sequence
anti-angiogenic treatment
Mynediad Ar-lein:https://www.frontiersin.org/articles/10.3389/fonc.2025.1675386/full
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg